A New Horizon of Hope: uniQure's AMT-130 Shines with Positive 3-Year Data in Huntington's Disease
Navigating the Path to Approval: Why REGENXBIO (RGNX) Remains a Strong Investment with RGX-121 for Hunter Syndrome